SCHEMBL8031275

SCHEMBL8031275

Cn1nc(C2CCCC2)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.53
PSMB9 P28065 1/20 0.53
PSMB5 P28074 1/20 0.53
KDM4E B2RXH2 1/20 0.47
GRN P28799 1/20 0.47
SORT1 Q99523 1/20 0.47
KMO O15229 1/20 0.44
KCNT1 Q5JUK3 4/20 0.42
PDK1 Q15118 2/20 0.40
PDK2 Q15119 2/20 0.40
CACNA1H O95180 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNJ6 P48051 1/20 0.38
KCNJ5 P48544 1/20 0.38
KCNJ3 P48549 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11899894 0.97 PSMB8 (0.50) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL2215374 0.93 KDM4E (0.50) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL30722924 0.86 PDK1 (0.46) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL23293556 0.83 KDM4E (0.42) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL27028206 0.83 KDM4E (0.42) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL17454397 0.79 PSMB8 (0.46) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL3997610 0.79 PSMB8 (0.53) PSMB8PSMB9PSMB5KDM4ENPC1
SCHEMBL3065968 0.78 KCNT1 (0.46) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL4072006 0.78 PSMB8 (0.45) PSMB8PSMB9PSMB5KDM4EGRN
SCHEMBL29058235 0.78 KMO (0.45) PSMB8PSMB9PSMB5KDM4EKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009071707-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2009-06-11 WO disclosed
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-10-02 US disclosed
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases GALAPAGOS NV (BE) 2008-10-02 US disclosed
WO-2008071650-A2 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242661-A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases PDE4A, PDE7B, PDE4B PSMB8 4084/4885PSMB9 4014/4885PSMB5 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.